1. Home
  2. ATYR vs SACH Comparison

ATYR vs SACH Comparison

Compare ATYR & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.72

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.07

Market Cap

47.5M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATYR
SACH
Founded
2005
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
47.5M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
ATYR
SACH
Price
$0.72
$1.07
Analyst Decision
Buy
Hold
Analyst Count
6
3
Target Price
$8.75
$2.00
AVG Volume (30 Days)
2.1M
274.2K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
19.42%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$190,000.00
$3,906,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$18,728.88
$1.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.80
52 Week High
$7.29
$1.40

Technical Indicators

Market Signals
Indicator
ATYR
SACH
Relative Strength Index (RSI) 41.09 50.88
Support Level $0.70 $0.99
Resistance Level $0.75 $1.05
Average True Range (ATR) 0.04 0.05
MACD 0.01 -0.00
Stochastic Oscillator 21.52 28.23

Price Performance

Historical Comparison
ATYR
SACH

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

Share on Social Networks: